Victory Capital Management Inc. Boosts Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Victory Capital Management Inc. boosted its stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 12.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 372,291 shares of the company's stock after acquiring an additional 40,482 shares during the period. Victory Capital Management Inc. owned 0.63% of Twist Bioscience worth $17,300,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB bought a new stake in shares of Twist Bioscience in the 3rd quarter worth approximately $34,000. Van ECK Associates Corp raised its stake in shares of Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after buying an additional 267 shares during the period. US Bancorp DE lifted its position in shares of Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after buying an additional 601 shares during the last quarter. Beaird Harris Wealth Management LLC bought a new position in shares of Twist Bioscience during the 3rd quarter worth $95,000. Finally, KBC Group NV increased its holdings in Twist Bioscience by 71.4% in the 4th quarter. KBC Group NV now owns 2,942 shares of the company's stock worth $137,000 after acquiring an additional 1,226 shares during the last quarter.

Analysts Set New Price Targets

TWST has been the subject of a number of research reports. TD Cowen reiterated a "buy" rating and set a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. Robert W. Baird raised their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a report on Tuesday, February 4th. JPMorgan Chase & Co. lifted their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research note on Tuesday, February 4th. Wolfe Research initiated coverage on Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 target price on the stock. Finally, Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Twist Bioscience presently has a consensus rating of "Moderate Buy" and an average price target of $54.40.

Remove Ads

Twist Bioscience Trading Up 6.6 %

Shares of TWST stock opened at $39.13 on Wednesday. The company has a market capitalization of $2.33 billion, a PE ratio of -11.58 and a beta of 2.15. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The business's fifty day moving average is $46.33 and its 200 day moving average is $45.43. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm had revenue of $88.70 million for the quarter, compared to analysts' expectations of $86.96 million. During the same quarter last year, the firm posted ($0.75) EPS. The company's revenue was up 24.1% compared to the same quarter last year. On average, equities research analysts anticipate that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Insider Activity at Twist Bioscience

In other news, CEO Emily M. Leproust sold 1,654 shares of the firm's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $44.90, for a total transaction of $74,264.60. Following the sale, the chief executive officer now owns 673,064 shares in the company, valued at approximately $30,220,573.60. This trade represents a 0.25 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Paula Green sold 1,259 shares of the company's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $62,131.65. Following the completion of the transaction, the senior vice president now owns 132,014 shares of the company's stock, valued at $6,514,890.90. This trade represents a 0.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,845 shares of company stock valued at $1,603,945 over the last three months. 3.01% of the stock is owned by corporate insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Co. (NASDAQ:TWST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.